🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 45828J103
- IPO
- 6/30/2023 · $5.00/share
Business: Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx℠ technology platform to create proprietary drug formulations that following direct injection rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors.
Company Contact
- CEO
- Lewis H. Bender
- CFO
- iJoseph Talamo
- Headquarters
- 1 Enterprise Drive, Suite 430, Shelton, CT 06484
- Phone
- 203-221-7381
- Investor Relations
- Michael K. Miller, Rx Communications Group · 917-633-6086 · mmiller@rxir.com